Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Socié, G; Schmoor, C; Bethge, WA; Ottinger, HD; Stelljes, M; Zander, AR; Volin, L; Ruutu, T; Heim, DA; Schwerdtfeger, R; Kolbe, K; Mayer, J; Maertens, JA; Linkesch, W; Holler, E; Koza, V; Bornhäuser, M; Einsele, H; Kolb, HJ; Bertz, H; Egger, M; Grishina, O; Finke, J.
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Blood. 2011; 117(23): 6375-6382.
Doi: 10.1182/blood-2011-01-329821
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P = .47, and HR = 0.68, P = .18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P = .39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P < .0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antilymphocyte Serum - administration and dosage
- Chronic Disease -
- Cyclosporine - administration and dosage
- Disease-Free Survival -
- Female -
- Graft vs Host Disease - mortality
- Hematologic Neoplasms - mortality
- Hematopoietic Stem Cell Transplantation -
- Humans -
- Immunosuppression - methods
- Immunosuppressive Agents - administration and dosage
- Male -
- Methotrexate - administration and dosage
- Middle Aged -
- Recurrence -
- Survival Rate -
- Time Factors -
- Transplantation Conditioning -
- Transplantation, Homologous -